Armstrong AW, Lebwohl M, Bagel J, Schlesinger T, Banerjee S, Kisa RM, Scharnitz T, Hoyt K, Strober B. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline body surface area (BSA) involvement and baseline Psoriasis Area and Severity Index (PASI). J of Skin [Internet]. 2023 Mar. 13 [cited 2024 Jul. 4];7(2):s120. Available from: https://jofskin.org/33014/index.php/skin/article/view/1959